Cargando…

Engineering chimeric antigen receptor-T cells for cancer treatment

Intratumor heterogeneity of tumor clones and an immunosuppressive microenvironment in cancer ecosystems contribute to inherent difficulties for tumor treatment. Recently, chimeric antigen receptor (CAR) T-cell therapy has been successfully applied in the treatment of B-cell malignancies, underscorin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Baixin, Stary, Creed M., Li, Xuejun, Gao, Qingping, Kang, Chunsheng, Xiong, Xiaoxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815249/ https://www.ncbi.nlm.nih.gov/pubmed/29448937 http://dx.doi.org/10.1186/s12943-018-0814-0

Ejemplares similares

Single-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and Research
por: Ye, Baixin, et al.
Publicado: (2016)

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
por: Ye, Baixin, et al.
Publicado: (2017)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
por: Hillerdal, Victoria, et al.
Publicado: (2015)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020)

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
por: Zhang, Yalan, et al.
Publicado: (2023)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014)

Chimeric antigen receptor–engineered T cells as oncolytic virus carriers
por: VanSeggelen, Heather, et al.
Publicado: (2015)

Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
por: Gavriil, Artemis, et al.
Publicado: (2020)

The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells
por: Hughes-Parry, Hannah E., et al.
Publicado: (2019)

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
por: Ito, Yusuke, et al.
Publicado: (2022)

Engineering chimeric antigen receptor T cells for solid tumour therapy
por: Liu, Longwei, et al.
Publicado: (2022)

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
por: Alhabbab, Rowa Y.
Publicado: (2020)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
por: Zhang, Erhao, et al.
Publicado: (2017)

Extracellular vesicle-derived miRNA as a novel regulatory system for bi-directional communication in gut-brain-microbiota axis
por: Zhao, Liang, et al.
Publicado: (2021)

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds
por: Kalos, Michael
Publicado: (2016)

Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells
por: Hale, Malika, et al.
Publicado: (2017)

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
por: Neeser, A., et al.
Publicado: (2023)

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
por: Ormhøj, Maria, et al.
Publicado: (2022)

Molecular Pathogenesis of Anti-NMDAR Encephalitis
por: Ding, Hao, et al.
Publicado: (2015)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Meisoindigo, but not its core chemical structure indirubin, inhibits zebrafish interstitial leukocyte chemotactic migration
por: Ye, Baixin, et al.
Publicado: (2016)

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
por: Hwang, Michael S., et al.
Publicado: (2021)

Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies
por: Mangal, Joslyn L., et al.
Publicado: (2021)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
por: Wang, Xiao, et al.
Publicado: (2022)

Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment
por: Terlikowska, Katarzyna M., et al.
Publicado: (2021)

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
por: Xiong, Wei, et al.
Publicado: (2018)

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
por: Xiong, Wei, et al.
Publicado: (2021)

Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors
por: Moot, Robert, et al.
Publicado: (2016)

Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells
por: Chen, Sisi, et al.
Publicado: (2022)

Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
por: Elahi, Reza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jm43qsfpq1cj3or2ifmkkpl3gu